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Abstract
Molecular quantitative trait locus (QTL) analyses are increasingly popular to explore the
genetic architecture of complex traits, but existing studies do not leverage shared regulatory
patterns and suffer from a large multiplicity burden, which hampers the detection of weak
signals such as trans associations. Here, we present a fully multivariate proteomic QTL
(pQTL) analysis performed with our recently proposed Bayesian method LOCUS on data
from two clinical cohorts, with plasma protein levels quantified by mass-spectrometry and
aptamer-based assays. Our two-stage study identifies 136 pQTL associations in the first
cohort, of which >80% replicate in the second independent cohort and have significant
enrichment with functional genomic elements and disease risk loci. Moreover, 78% of the
pQTLs whose protein abundance was quantified by both proteomic techniques are con-
firmed across assays. Our thorough comparisons with standard univariate QTL mapping on
(1) these data and (2) synthetic data emulating the real data show how LOCUS borrows
strength across correlated protein levels and markers on a genome-wide scale to effectively
increase statistical power. Notably, 15% of the pQTLs uncovered by LOCUS would be
missed by the univariate approach, including several trans and pleiotropic hits with success-
ful independent validation. Finally, the analysis of extensive clinical data from the two
cohorts indicates that the genetically-driven proteins identified by LOCUS are enriched in
associations with low-grade inflammation, insulin resistance and dyslipidemia and might
therefore act as endophenotypes for metabolic diseases. While considerations on the clini-
cal role of the pQTLs are beyond the scope of our work, these findings generate useful
hypotheses to be explored in future research; all results are accessible online from our
searchable database. Thanks to its efficient variational Bayes implementation, LOCUS can
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Author summary
Exploring the functional mechanisms between the genotype and disease endpoints in
view of identifying innovative therapeutic targets has prompted molecular quantitative
trait locus studies, which assess how genetic variants (single nucleotide polymorphisms,
SNPs) affect intermediate gene (eQTL), protein (pQTL) or metabolite (mQTL) levels.
However, conventional univariate screening approaches do not account for local depen-
dencies and association structures shared by multiple molecular levels and markers. Con-
versely, the current joint modelling approaches are restricted to small datasets by
computational constraints. We illustrate and exploit the advantages of our recently intro-
duced Bayesian framework LOCUS in a fully multivariate pQTL study, with�300K tag
SNPs (capturing information from 4M markers) and 100 − 1, 000 plasma protein levels
measured by two distinct technologies. LOCUS identifies novel pQTLs that replicate in an
independent cohort, confirms signals documented in studies 2 − 18 times larger, and
detects more pQTLs than a conventional two-stage univariate analysis of our datasets.
Moreover, some of these pQTLs might be of biomedical relevance and would therefore
deserve dedicated investigation. Our extensive numerical experiments on these data and
on simulated data demonstrate that the increased statistical power of LOCUS over stan-
dard approaches is largely attributable to its ability to exploit shared information across
outcomes while efficiently accounting for the genetic correlation structures at a genome-
wide level.
Introduction
Questioning the genetic contribution to human diseases has become a critical step towards
predicting health risks and developing effective therapies [1–3]. However the functional net-
work of interacting pathways between the genotype and disease endpoints largely remains a
“black box”, so the expected transformation of medicine has only begun. The analysis of endo-
phenotypes such as gene, protein or metabolite levels, via molecular quantitative trait locus
(QTL) studies may provide deeper insight into the biology underlying clinical traits [3]. While
eQTL studies are now routinely performed, pQTL studies have emerged only recently [4–9].
These studies allow the exploration of the genetic bases of several diseases, as certain proteins
may act as proxies for specific clinical endpoints [10]. However two major hurdles hamper
pQTL analyses. First, owing to the number of tests that they entail, conventional univariate
approaches lack statistical power for uncovering weak associations, such as trans and pleiotro-
pic effects [11–13], while better-suited multivariate methods fail to scale to the dimensions of
QTL studies. Second, the clinical data complementing QTL data are often very limited,
restricting subsequent investigation to external information from unrelated populations,
health status or study designs, and rendering some degree of speculation unavoidable.
In this paper, we demonstrate that both concerns can be addressed using statistical
approaches and data tailored to the problem under consideration: we present an integrative
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genome-wide pQTL study of two clinical cohorts performed with our Bayesian joint QTL
method LOCUS [14], which simultaneously accounts for all the genetic variants and proteo-
mic outcomes, thereby leveraging the similarity across proteins controlled by shared func-
tional mechanisms. We employ a two-stage design, using data from the Ottawa cohort (n = 1
644) [15] for discovery and replicating our findings in the independent DiOGenes cohort
(n = 789) [16]. Each dataset involves protein plasma levels quantified by mass-spectrometry
(MS) and aptamer-based (SomaLogic, [17]) assays, which permits thorough cross- and intra-
platform validation.
Our work aims to illustrate the utility and feasibility of multivariate Bayesian QTL analyses.
Notably, we show the gain in statistical power achieved by LOCUS on our data by confronting
the validated hits with those of a classical two-stage univariate design. We also assess the per-
formance of both approaches in simulations mimicking real data conditions.
Pertinent interpretation of pQTL loci in the context of complex diseases hinges on a careful
examination of metabolic and clinical parameters from the same subjects or, at a minimum,
from a population presenting similar clinical characteristics. Using comprehensive data from
the two pQTL cohorts, we evaluate the enrichment of the proteins under genetic control for
associations with clinical parameters; this assessment suggests that our pQTL findings may
ease the identification of proteomic biomarkers and calls for further dedicated research. All
results are available from our online browser https://locus-pqtl.epfl.ch/db.
Results
Two-stage pQTL analyses
We analyzed the pQTL data from the Ottawa and DiOGenes cohorts in a two-stage study. The
DiOGenes cohort recruited overweight/obese, non-diabetic subjects, while the Ottawa study
was led in a specialized obesity practice where subjects had severe obesity, dyslipidemia and
insulin resistance disorders (S1 Table).
We used LOCUS ([14], Material and methods and Fig 1a–1c) for joint analyses of both
proteomic datasets from the Ottawa cohort, quantified by MS and the multiplexed aptamer-
based technology SomaLogic [17], respectively. We adjusted all analyses for body mass index
(BMI), age and gender. At FDR 5%, LOCUS identified 18 pQTL associations from the MS
analysis, corresponding to 14 unique proteins and 18 SNPs, and 118 pQTLs from the SomaLo-
gic analysis, corresponding to 99 proteins and 111 SNPs (S2 Table). We then undertook to rep-
licate all uncovered pQTLs in the independent DiOGenes cohort, using MS and SomaLogic
data. We validated 15 of the 18 discovered MS pQTLs, and 98 of the 118 discovered SomaLogic
pQTLs at FDR 5% (S3 Table), yielding a replication rate of 83% in both cases (Fig 1d).
We evaluated replication rates separately for cis and trans effects. With the MS data, all 15
cisOttawa pQTLs replicated in DiOGenes, while the 3 trans pQTLs did not. With the SomaLo-
gic data, 78 of 81 cis and 20 of 37 trans pQTLs could be validated (Fig 2c). The overall replica-
tion rates reached 97% for the cis pQTLs and 50% for the trans pQTLs; the trans-pQTL rate is
in line with other pQTL studies [4, 7, 8]. Finally, 35 of our validated pQTLs are, to our knowl-
edge, new, i.e., they do not overlap with pQTLs previously identified in the general population
[4, 6–9], and this number drops to 20 using proxy search r2 > 0.8; four of these 20 hits have
isoforms involved in known pQTLs, see S4 Table for the complete list.
Cross-assay validation
The relative merits of MS untargeted and multiplexed aptamer-based techniques for quantify-
ing protein abundance have been a subject of active debate over the past years [18], [19]. On
one hand, the former usually demonstrate very high specificity, but are limited in dynamic
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range and in their sensitivity to detect low abundance proteins. On the other hand, the latter—
and in particular the recent SOMAscan technology provided by SomaLogic [17]—can target
proteins across a wide dynamic range and include lowly expressed proteins not accessible to
MS approaches, but are more subject to binding artefacts caused by the multiplexing. Hence,
although rapidly improving, the two techniques remain complementary, and the combination
of measurements by both approaches offers a convenient balance between specificity and
sensitivity.
Fig 1. LOCUS model overview and study workflow. (a) Inputs to LOCUS are an n × p design matrix X of p SNPs, and an n × q outcome matrix y of q
molecular traits, e.g., gene, protein, lipid, metabolite or methylation levels, for n individuals. The model accounts for all the SNPs and molecular traits
jointly. (b) Graphical model representation of LOCUS. The effect between a SNP s and a trait t is modelled by βst, and γst is a latent variable taking value
unity if they are associated, and zero otherwise. The parameter ωs controls the pleiotropic level of each SNP, i.e., the number of traits with which it is
associated. The parameter σ represents the typical size of effects, and the parameter τt is a precision parameter that relates to the residual variability of
each trait t. (c) Outputs of LOCUS are posterior probabilities of associations, pr(γst = 1 j y), for each SNP and each trait (p × q panel), and posterior
means for the pleiotropy propensity of each SNP, E(ωs j y) (Manhattan plot). (d) Workflow of the pQTL study. The MS and SomaLogic pQTL data are
analyzed in parallel. LOCUS is applied on the Ottawa data for discovery, and 83% of the 18 and 118 pQTL associations discovered with the MS and
SomaLogic data replicate in the independent study DiOGenes. The possible relevance of the validated pQTLs for disease endpoints is explored via
analyses of clinical parameters from the Ottawa and DiOGenes cohorts. Further support is obtained by evaluating the overlap with eQTLs, epigenomic
marks and GWAS risk loci.
https://doi.org/10.1371/journal.pcbi.1007882.g001
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In the Ottawa and DiOGenes studies, a subset of 72 proteins was quantified by both the MS
and SomaLogic techniques (S1 Appendix). For the pQTLs whose protein had dual measure-
ment, this enabled an additional layer of validation with the alternative assay, on top of direct
within-assay validation. Eight of the MS pQTLs could be assessed with SomaLogic (i.e., had
protein levels available), and 7 of them replicated at FDR 5%. Likewise, of the 20 SomaLogic
associations having MS measurements, 14 were confirmed (S3 Table). Moreover, the cross-
assay correlation of estimated effects for the pQTLs with successful dual validation was high,
ρ = 0.93, providing further support to our findings (Fig 2b).
Specificity issues and experimental platform-inherent variability might explain why the
remaining seven pQTLs could not be confirmed using the alternative technology. Indeed,
although most protein expression patterns quantified by the two technologies were in good
agreement, some were not, in particular, the between-technology correlation for the geneti-
cally-driven protein levels HEMO, HGFA, LYSC and PON1 was lower than 0.25 in the two
cohorts (S1 Appendix). In line with this hypothesis, recent work by Kim and colleagues [19]
concluded on an overall good reproducibility with SomaLogic, yet with some non-negligible
Fig 2. Overview of LOCUS validated pQTL hits. (a) Venn diagram for the locus-protein hits identified by the
GEMMA and LOCUS two-stage analyses. The hits uncovered by GEMMA but not by LOCUS (left) and the hits
uncovered by LOCUS but not by GEMMA (right) are listed; the stars indicate that the former were not tagged so not
detectable by the LOCUS analyses. When multiple SNPs correspond to the same locus-protein hit, the SNP(s) with the
top association(s) in the Ottawa cohort is/are shown. The novel hits (r2 > 0.8-proxy search) are in bold and the hits
with dual replication in the alternative proteomic platform are marked with a cross (4 over the 4 quantified with both
platforms). (b) Estimated effects (regression coefficients with standard errors) in DiOGenes for the validated pQTLs
whose controlled protein is quantified by both technologies (S3 Table). (c) Circular plot for the trans-pQTL
associations uncovered by LOCUS (FDR<5% for discovery and validation). Each arrow starts from the pQTL SNP
with label indicating its closest gene (grey) and points to the gene (black) coding for the controlled protein. The
proteins whose trans pQTLs are missed by GEMMA are highlighted in green.
https://doi.org/10.1371/journal.pcbi.1007882.g002
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technical variability (intra-class correlation coefficient� 0.4 for 91 of the proteins that they
tested).
Comparison with a standard univariate pQTL analysis
There is a broad consensus in the biostatistical community about the benefits of collectively
accounting for all SNPs while leveraging information across multiple correlated outcomes
[20–22]. However, many also acknowledge the mathematical and computational difficulties
hampering these practices in genome-wide association or QTL studies [23], [24]. Pilot simula-
tion experiments using LOCUS [14] have indicated that its flexible hierarchical sparse regres-
sion model coupled with a scalable variational inference scheme (Fig 1a–1c) can effectively
increase statistical power at the scale required by current molecular QTL studies. Here we pro-
vide sound practical evidence—in the context of the Ottawa and DiOGenes studies and based
on thorough comparisons with the classical univariate screening design—that this tailored
multivariate framework can lead to higher replication rates and novel pQTL discoveries.
Namely, we compare LOCUS with the univariate linear mixed model approach GEMMA [25,
26] in two complementary ways. First, we use synthetic data to repeatedly evaluate their vari-
able selection performance for a series of data scenarios where the ground truth (here QTL
associations) is known since simulated. Second, we confront the findings (number of cis/trans
locus-protein hits detected, replication rates) of LOCUS two-stage analysis to those obtained
by re-analyzing the Ottawa and DiOGenes datasets with GEMMA.
Simulations. Simulation studies can be far from reflecting real data scenarios. To best
emulate our study and obtain a realistic assessment of the relative performance of the multivar-
iate and univariate approaches, special care was taken to use synthetic data that resemble the
real data and embody accepted principles of population genetics (Material and methods). In
particular, we employed real SNPs from our study as candidate predictors and we simulated
proteomic levels by replicating the block-correlation structure and variability of the 133 MS
protein levels, using our freely available data generator echoseq. A comparison of the syn-
thetic and real proteomic levels is provided in S2 Appendix.
The first simulation study uses the SNPs from chromosome one of the Ottawa cohort and
the 133 outcomes mimicking the MS proteomic levels, enforcing that the SNPs explain
together at most 35% of each protein variance (Material and methods). The ROC curves (Fig
3a) show a net gain in power for selections with LOCUS compared to GEMMA. The average
standardized partial areas under the curve (pAUC) with 95% confidence intervals are 0.926
±0.005 for LOCUS and 0.840±0.005 for GEMMA. The second simulation study generalizes
this observation for a grid of data generation scenarios with different effect sizes and numbers
of proteins under genetic control: the average standardized pAUCs (Fig 3b) are greater for
LOCUS than for GEMMA in most cases and are comparable for very low proportions of pro-
tein variance explained by the SNPs.
By design, univariate screening approaches do not exploit association patterns common to
multiple outcomes or markers; they analyze the outcomes individually, and do not account for
linkage disequilibrium (LD), which often results in a number of redundant proxy discoveries
at loci with strong LD (Fig 3c). At a given FDR, this hampers the detection of weak but genuine
signals because of the large multiple testing burden. Post-processing strategies accounting for
local LD structures exist [27, 28] and alleviate the problem to some extent. Instead of applying
such corrections, LOCUS anticipates and addresses the question by enforcing sparsity directly
at the modelling stage. It better discriminates truly associated SNPs from their correlated
neighbours (Fig 3c), owing to its simulated annealing procedure. We do not claim that
LOCUS can provide direct information on the regulatory potential of individual variants in
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real data settings, as this always requires follow-up studies at the level of loci, e.g., using fine-
mapping analyses or in-lab experiments. We do argue however that its effective handling the
LD structures can improve the selection of candidate variants for these subsequent functional
studies, which may save substantial research investment.
Fig 3. Selection performance of LOCUS and GEMMA on simulated data. (a) Truncated average ROC curves with
95% confidence intervals (50 replicates) for the detection of SNP-trait associations. (b) Average standardized partial
AUC of LOCUS and GEMMA for a grid of effect sizes (x-axis) and signal sparsity (y-axis, 20 replicates for each
scenario). (c) Simulated association pattern and patterns recovered by LOCUS and GEMMA, averaged over the 50
replicates. The plots display a window of 350 SNPs (x-axis) containing the first three SNPs with simulated associations
(blue labels), along with their LD pattern. (d) Average standardized AUC with 95% confidence intervals for different
numbers of proteins modelled jointly, i.e., the 133 simulated proteins are randomly partitioned into batches of size q0
(x-axis) and LOCUS is applied separately on these batches: q0 = 1 corresponds to modelling the proteins one by one
and q0 = 133 corresponds to modelling all 133 proteins jointly, as achieved by a classical application of LOCUS. (e)
Posterior mean of the LOCUS parameter representing the propensity for SNPs to be pleiotropic. Its magnitude
satisfactorily reflects the number of simulated associations per SNP (color-coded).
https://doi.org/10.1371/journal.pcbi.1007882.g003
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Finally, the improvement over GEMMA and other classical approaches also comes in large
part from the capacity of LOCUS to handle all correlated outcomes jointly, thereby borrowing
strength across them. This is illustrated in our third simulation study (Fig 3d), whereby
LOCUS is applied separately to multiple outcome batches of increasing sizes, from one protein
per batch, corresponding to a univariate treatment of each proteomic outcome, to all 133 sim-
ulated proteins, corresponding to a regular application of our method. The pAUCs indicate a
significant increase of power when the outcomes are modelled jointly, as shared information
across them can be effectively exploited to enhance the detection of weak effects. Technically,
this shared information feature is mainly achieved via a specific model parameter, ωs (Fig 1b),
which directly reflects the propensity of each SNP to be pleiotropic, i.e., to be associated with
multiple outcomes (Fig 3e); we will return to the practical value of this parameter in the discus-
sion of a pleiotropic locus identified in the real data study. Finally, we emphasize that our fully
joint analysis is only possible thanks to the efficient variational inference implementation of
LOCUS which supersedes the prohibitively slow Markov chain Monte Carlo (MCMC) rou-
tines traditionally employed for Bayesian inference.
These simulations tailored to the real data at hand prefigure the gain of power achieved by
LOCUS over standard methods for our pQTL study, as we next discuss.
Performance on the real data. We now compare LOCUS and GEMMA on the real data
under the typical two-stage GWA scenario employed in pQTL studies [4, 8, 9]. Namely, we
contrast the results of LOCUS with those of GEMMA applied to the Ottawa and DiOGenes
data, but this time considering all 4M SNPs available before LD pruning and employing a stan-
dard genome-wide Bonferroni correction of α = 0.05. We acknowledge that the 0.05-Bonfer-
roni correction may be overly conservative and also discuss the results using a permissive
0.2-Bonferroni threshold (Material and methods).
The number of locus-protein hits identified and replicated with at least one of the two
methods was 100, using Bonferroni correction of 0.05 for GEMMA (full list of SNP-protein
hits in S5 Table and summarized by sentinel SNPs in S6 Table). Among these 100 hits,
GEMMA missed 15 hits validated by LOCUS (9 with the permissive Bonferroni correction of
0.2). As many as 5 of these 15 hits were trans associations and 6/15 hits were not previously
described in the literature using a r2 > 0.5-proxy search (Fig 2a and S5 Table); these two obser-
vations highlight again the ability of LOCUS to identify weak/trans effects that may go unno-
ticed by univariate analysis, in line with the above simulation studies. Moreover, all 4 hits
whose protein was quantified by both proteomic technologies had a successful dual replication
using the alternative technology.
Inspecting the estimates for the loci missed by GEMMA and validated by the LOCUS two-
stage analyses indicates that some univariate signal is present but is too weak to be detected
after multiplicity correction. In contrast, the multiplicity-adjusted LOCUS analyses could
effectively single out and validate individual hits among the strongest GEMMA signals. The S3
Appendix provides regional association plots for six such examples: three loci associated with
the CO7, ECM1 and ITIH3 MS levels, and three loci associated with the I17RB, PROC and
TENA SomaLogic levels. Moreover, the superiority of LOCUS appears to be robust to the p-
value threshold used for the univariate analysis: the replication rates and number of loci vali-
dated by GEMMA univariate design for a range of thresholds are inferior to those of LOCUS
multivariate design (S3 Appendix).
Finally, LOCUS missed 6 locus-protein hits identified by GEMMA, but, importantly, these
hits were not detectable by LOCUS. Indeed, all 115 SNPs selected by GEMMA had been
removed by the r2 > 0.95 pruning employed to define the tag SNP panel used for the LOCUS
study. To assess whether LOCUS would have identified these hits were their corresponding
loci included in the primary analysis, we reran our method after adding to our original panel
PLOS COMPUTATIONAL BIOLOGY A fully joint Bayesian QTL mapping of human protein abundance in plasma
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all 115 SNPs and their neighbours (1Mb span). LOCUS could successfully identify all 6 locus-
protein hits with very high posterior probabilities of inclusion (PPI >0.99). The sentinel SNPs
selected by LOCUS are reported in the “LOCUS extended panel” column of S6 Table.
In summary, the improvement, seen in the simulation study, of the multivariate design
over the classical univariate design is confirmed on the real data: LOCUS achieves higher repli-
cation rates, uncovers 15 pQTL loci missed by univariate screening (and does not miss any
univariate signal when the corresponding SNPs are properly included in the tag-SNP panel).
Among the hits missed by the univariate design but validated by LOCUS two-stage analysis,
several are trans signals (proteins: INSR, PROC, SEM3A, TENA, XRCC6, i.e., 5/15), novel sig-
nals (CYTN, CYTT, FA12, FCN3, ITIH3, XRCC6, i.e., 6/15) and have successful cross-assay
validation using the MS and SomaLogic measurements of their protein if available (CFAB,
CO7, ECM1, XRCC6, i.e., 4/4).
Two examples: A pleiotropic locus and a trans-acting locus
In this section we examine the advantages of our multivariate analysis for the detection of two
loci, i.e., the notorious pleiotropic locus ABO and a novel locus on chromosome 11 trans-act-
ing on the XRCC6 levels. These two examples are representative of the types of signals which
LOCUS tends to better detect, namely weaker signals, possibly involving a shared control from
a single locus. We also formulate some hypotheses on the involvement of these pQTLs in meta-
bolic health, to be explored in dedicated studies.
The recovery of the ABO signals by LOCUS was facilitated by its tailored parametrization
that directly models pleiotropy via ωs, as discussed in the simulation section and shown in Fig
3e. Fig 4a indicates that LOCUS piled up evidence on the two sentinels SNPs rs2519093 and
rs8176741. Althougth the functional relevance of these two SNPs is by no means guaranteed
and would need to be inspected in proper wet-lab or fine-mapping experiments, LOCUS
could capitalize on the pleiotropic potential of these SNPs to effectively exploit the shared asso-
ciations across the five proteins. Presumably because GEMMA does not leverage joint patterns
across proteins, the univariate estimates failed to reach significance for the INSR protein, even
using a loose Bonferroni threshold of α = 0.2.
ABO is a well-known pleiotropic locus associated with coronary artery diseases, type 2 dia-
betes, liver enzyme levels (alkaline phosphatase) and lipid levels [4, 5, 7]. Our analyses
highlighted two independent sentinel SNPs in the ABO region: rs2519093 and rs8176741 (r2 =
0.03). The former SNP is trans-acting on E-selectin (protein LYAM2 encoded by SELE), the
Insulin Receptor and the CD209 antigen. The latter SNP is trans-acting on the Tyrosine-pro-
tein kinase receptor (Tie-1), Cadherin-5 and CD209. Both SNPs were reported as cis-acting
eQTL variants for ABO, OBP2B and SURF1, and further queries in public databases indicated
that rs8176741 may affect the binding sites for three transcription factors (Myc, MYC-MAX
and Arnt), suggesting a complex gene regulation circuitry.
Our analyses of the clinical parameters measured in the Ottawa and DiOGenes studies
found significant associations of the controlled proteins with several clinical variables, such as
triglycerides, visceral fat, fasting insulin, fasting glucose and HDL (Fig 5); this suggests that the
ABO locus might have a role in metabolic health, although further research is needed to con-
firm this. In particular, the CD209 protein could be a secreted protein, released by M2 macro-
phages from adipose tissue, with a beneficial role in controlling lipid levels, thereby possibly
protecting from developing dyslipidemia and related metabolic complications; see S4 Appen-
dix for further discussion.
Finally, some proteins had been reported as associated with the ABO locus [4] and yet did
not pop up in our analyses (nor in the GEMMA analyses), namely, BCAM, LYAM3 (SELP),
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MET, NOTC1, OX2G (CD200), TIE2 (TEK), VGFR2 (KDR), VGFR3 (FLT4), VWF. Multiple
reasons could explain this lack of significance, including but not only: the use of samples from
the obese population where these signals may be absent, a lack of statistical power and/or a
poor quality of the SomaLogic measurements. For TIE2 and VGFR3, LOCUS reported very
weak signals (PPI <0.1) suggesting insufficient power. As for the other absent signals, the
hypothesis of poorly quantified SomaLogic levels is not unlikely but difficult to assess since all
seven proteins were measured only in the SomaLogic assay only and could therefore not be
compared to corresponding MS measurements.
Our second example concerns the variant rs4756623 identified by LOCUS as a novel trans
pQTL for the XRCC6 levels (X-Ray Repair Complementing Defective Repair In Chinese Ham-
ster Cells; also known as Ku70). Proxy searches (down to r2 = 0.5 in European ancestry panels)
did not reveal any tag SNP previously reported as a QTL (including e-, p-, or m-QTL). Again,
the univariate screening results indicated some trans signal between rs4756623 and XRCC6,
but the effect did not survive the multiplicity correction (Fig 4b).
The XRCC6 gene activates DNA-dependent protein kinases (DNA-PK) to repair double-
stranded DNA breaks by nonhomologous end joining. DNA-PKs have been linked to
Fig 4. Two examples of pQTL signal estimation in the discovery set. (a) The pleiotropic locus ABO: The panel “LOCUS pleiotropy parameter in
ABO” shows the posterior mean E(ωs j y) for a 1 Mb region around the gene ABO. This quantity attributes weight to two SNPs, rs8176741 and
rs2519093, which LOCUS finds associated with the proteins CADH5, CD209, TIE1, resp., CD209, INSR, LYAM2. For each of these proteins, the
colored panel displays the −log10 nominal p-values obtained when re-analyzing the Ottawa data with GEMMA [25, 26]; the dashed and dotted
horizontal lines show the Bonferroni level of α = 0.05, resp. α = 0.2. The pleiotropic SNP identified by LOCUS is marked with a green triangle
(rs8176741 left column, rs2519093 right column), and its correlation in r2 with the surrounding SNPs is indicated by the yellow to red colors. The top
SNP found by GEMMA is shown by a black star; the univariate signal for INSR does not pass the p-value significance thresholds yet is detected by
LOCUS multivariate analyses. (b) A locus trans-acting on XRCC6 (same labelling as in (a)).
https://doi.org/10.1371/journal.pcbi.1007882.g004
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lipogenesis in response to feeding and insulin signaling [29]. DNA-PK inhibitors may reduce
the risk of obesity and type 2 diabetes by activating multiple AMPK targets [30]. A recent
review discussed the role of DNA-PK in energy metabolism, and in particular, the conversion
of carbohydrates into fatty acids in the liver, in response to insulin [31]. It described increased
DNA-PK activity with age, and links with mitochondrial loss in skeletal muscle and weight
gain. Finally, XRCC6 functions have been reported as associated with regulation of beta-cell
proliferation, islet expansion, increased insulin levels and decreased glucose levels [30, 32].
We found that XRCC6 was significantly associated with decreased HDL, increased triglyc-
erides, insulin levels and visceral adiposity in our studies, while rs4756623 is located within the
LRRC4C gene a binding partner for Netrin G1, which has a known role in metabolism (S4
Appendix); the regulatory mechanisms between the rs4756623 locus and the XRCC6 levels
should be clarified, and functional studies will be required to understand their physiological
impact.
The next three sections provide a general characterization of the pQTLs identified by
LOCUS in terms of their functional enrichment, overlapping patterns with known loci and
clinical relevance of their associated proteins.
Overlap with eQTLs and evidence for regulatory impact
We assessed the overlap of the 113 validated pQTLs with known eQTLs (S7 Table). Seventy-
seven of the 104 sentinel SNPs involved in our pQTL associations had one or more eQTL asso-
ciations in at least one tissue. These SNPs have been implicated in 83 eQTL associations,
Fig 5. Forest plots for associations between proteins under genetic control and clinical parameters. Analyses were
adjusted for age, gender and BMI (Material and methods) and the selection of proteins shown covers the ABO and
XRCC6 pQTLs discussed in the main text as well as other examples discussed in S4 Appendix. All endpoints are
measured in both the Ottawa and DiOGenes cohorts; they correspond to total lipid levels (first row: total cholesterol,
HDL, LDL, triglycerides), glucose/insulin resistance (second row: fasting glucose, fasting insulin, HOMA-IR) and the
visceral adiposity index (VAI). In each case, regression coefficients with 95% confidence intervals are shown for the
Ottawa and DiOGenes analyses, and for the meta-analysis. The stars indicate associations with meta-analysis FDR
<5% (correction applied across all proteins under genetic control, not only those displayed). For proteins with
measurements in the MS and SomaLogic platforms, association results are displayed for both; trans-regulated proteins
are in bold.
https://doi.org/10.1371/journal.pcbi.1007882.g005
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representing a significant enrichment (p< 2.2 × 10−16). Forty-nine of these 77 SNPs were
eQTL variants for the gene coding for the protein with which they were associated in our
datasets. Our pQTLs were also enriched in epigenome annotation marks (p = 9.20 × 10−4)
and significantly closer to transcription start sites compared to randomly chosen SNP sets
(p = 9.99 × 10−6). These observations suggest potential functional consequences for our pQTL
hits.
Overlap with GWAS risk loci
A total of 217 previously reported genome-wide associations overlapped our validated pQTL
loci, corresponding to 139 unique traits mapping to 68 distinct regions (based on LD r2 > 0.8).
Nineteen SNPs were directly involved in these associations (S8 Table) representing a signifi-
cant enrichment (p< 2.2 × 10−16).
This suggests that studying the genetic associations with the proteome may serve as starting
point to elucidate the molecular processes between the genotype and certain clinical endpoints
whose genetic control has been confirmed, and acquire mechanistic insights on the pathways
involved. Colocalization analyses are a first step towards this end. The next section also paves
the way for a discussion on the clinical relevance of our pQTL results by studying associations
with metabolic parameters directly measured in the Ottawa and DiOGenes studies.
Proteins as endophenotypes to study the genetic architecture of clinical
traits
As briefly illustrated in the discussion of the XRCC6 trans effect and the ABO pleiotropy, the
large panel of clinical variables pertaining to metabolic health measured in both the Ottawa
and DiOGenes studies is a rich resource for evaluating the possible biomedical value of the val-
idated pQTLs.
We performed a meta-analysis of the DiOGenes and Ottawa clinical and proteomic data,
and found that 35 of the 88 proteins under genetic control had associations with dyslipidemia,
insulin resistance or visceral fat-related measurements at FDR 5%. These associations should
be attributable metabolic factors independently of overall adiposity, as we controlled for BMI
as a potential confounder; they are listed and displayed as a network in S4 Appendix. We
observed consistent directions of effects in the two cohorts (see examples of Fig 5, and S9
Table for full details). Based on these associations, S4 Appendix expands on the possible bio-
medical relevance of a selection of pQTLs in the context of metabolic complications.
Importantly, the set of 88 genetically-driven proteins was significantly more associated with
the clinical variables compared to protein sets chosen randomly among all proteins quantified
by our MS and SomaLogic panels (p = 0.014), with this background adjustment accounting for
the bias of SomaLogic proteins towards specific inflammation and oncology-related pathways
(S10 Table). This enrichment therefore supports that the primary pQTL analyses can help
uncover potential proteomic biomarkers for the Metabolic Syndrome and related pathologies;
the full pQTL results of S4 Table and meta-analysis clinical associations of S9 Table constitute
a useful resource to this end.
Discussion
Despite important technological advances, large-scale pQTL studies remain infrequent, owing
to their high costs [4–9]. To date, due to a lack of scalable multivariate methods, current QTL
analyses rely on single-SNP/single-protein mapping, which inherently limits their findings to
loci displaying strong effect sizes.
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Here, we described the first integrative pQTL study that analyzes jointly all SNPs and prote-
omic levels from complementary MS and aptamer-based assays. Our Bayesian approach
LOCUS confirmed 93 pQTLs (75 distinct proteins) highlighted in previous studies [4, 6–9],
despite our sample sizes 2.5 to 18 times smaller, and revealed 20 novel pQTLs (18 distinct pro-
teins, S4 Table) with sound evidence for functional relevance and possible implications in the
development of the Metabolic Syndrome. Our two-stage analysis achieved very high replica-
tion rates (83%), and appreciable cross-technology validation for the pQTLs whose proteins
had dual-assay measurements (78%). Importantly, 15% of the validated findings would have
been missed by a standard univariate design.
This corroborates our extensive simulation studies, which demonstrated the improved QTL
detection of LOCUS compared to univariate approaches on synthetic data mimicking the real
data. In particular, these experiments indicated that the joint modelling of all outcomes leads
to a significant increase of power in scenarios where a shared regulatory architecture governs
groups of molecular levels. They also showed that accounting for local linkage disequilibrium
using simulated annealing further enhances the detection of weak effects and drastically
reduces the multiplicity burden. These advantages were exemplified for the pleiotropic locus
ABO and a novel locus trans-acting on XRCC6, and can be particularly important on datasets
with small sample sizes.
Finally, our analyses indicated that proteins under genetic control are enriched in associa-
tions with metabolic parameters, which supports a genetic basis of these parameters and
emphasizes the advantages of pQTL studies for elucidating their underlying functional mecha-
nisms. Evaluating the genetic control of plasma protein levels has the potential to reveal circu-
lating biomarkers of direct interest for diagnostic applications but clearly, large pQTL studies
in adipose tissues or liver may provide further, more specific insights on the role of the prote-
ome in metabolic health. Although still at their early stages, pQTL studies are also intrinsically
limited by the invasive nature of accessing tissues in humans. We hope that future progress in
the availability of tissue-specific proteomic samples will reveal new mechanisms unavailable
from plasma studies. As it is likely that sample sizes will remain limited, our well-powered
joint approach will be a useful tool to this end. In the meantime, our complete plasma pQTL
and clinical association results offer opportunities to study functional mechanisms and possi-
ble therapeutic options; they are accessible from the searchable online database https://locus-
pqtl.epfl.ch/db.
Our work presents a direct illustration of a fully joint QTL analysis at scale and highlights
concrete biological findings that take advantage of our tailored statistical approach. A central
ambition was to showcase that LOCUS can bridge the gap between Bayesian multivariate
inference and its practical use for analyzing current molecular QTL data. Indeed, the applica-
bility of LOCUS goes beyond pQTL studies, as it is tailored to any genomic, proteomic, lipido-
mic, metabolic or methylation QTL analyses and can be used for genome-wide association
with several clinical endpoints. The computational burden involved in most Bayesian infer-
ence approaches has hampered the use of multivariate hierarchical modelling on large molecu-
lar QTL datasets thus far; our joint framework overcomes this with a scalable batch-wise
variational algorithm and an effective C++/R implementation. It therefore offers a direct alter-
native to univariate screening approaches whose drawbacks for uncovering weak QTL effects
are the object of a broad consensus [11–13]. Performance profiling for LOCUS demonstrated
that it can analyze millions of SNPs and thousands of molecular levels (S2 Appendix). To our
knowledge, no other fully multivariate method is applicable to large molecular QTL studies
without drastic preliminary dimension reduction; our pilot study therefore opens new per-
spectives for uncovering weak and complex effects.
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Material and methods
Ethics approval and consent to participate
The Ottawa and DiOGenes studies were approved by the local human research ethic commit-
tees. Participants provided informed written consent, and all procedures were conducted in
accordance with the Declaration of Helsinki. Trial registration number: NCT00390637. Regis-
tered 20 October 2006.
Study samples
The Ottawa study was a medically supervised program set up by the Weight Management
Clinic of Ottawa [15]. Subjects under medication known to affect weight, glucose homeostasis
or thyroid indices were excluded from all analyses.
The DiOGenes study was a multi-center pan-European program [16]. Eight partner states
participated to the study: Bulgaria, the Czech Republic, Denmark, Germany, Greece, the Neth-
erlands, Spain and the United Kingdom. Participants were overweight/obese (BMI between 27
and 45 kg/m2), non-diabetic and otherwise healthy.
For both studies, subjects who were not under fasting conditions at plasma sample collec-
tion were excluded from the proteomic analyses. The main clinical characteristics of the
cohorts are given in S1 Table.
Proteomic data
Plasma protein expression data were obtained using two types of technologies: mass-spectrom-
etry (MS) and a multiplexed aptamer-based assay developed by SomaLogic [17]. Samples were
randomized, ensuring that the plate numbers were not associated with age, gender, ethnicity,
weight-related measures, glycemic indices, measures of chemical biochemistry, and, for the
DiOGenes samples, collection centers.
The MS proteomic quantification used plasma samples spiked with protein standard lacto-
globulin (LACB). Samples were immuno-depleted, reduced, digested, isobarically 6-plex
labeled and purified. They were analyzed in duplicates on two separate but identical systems
using linear ion trap with Orbitrap Elite analyzer and Ultimate 3000 RSLCnano System
(Thermo Scientific). Protein identification was done with the UniProtKB/Swiss-Prot database
[33], using Mascot 2.4.0 (Matrix Sciences) and Scaffold 4.2.1 (Proteome Software). Both pep-
tide and protein false discovery rates (FDR) were set to 1%, with a criterion of two unique pep-
tides. The relative quantitative protein values corresponded to the log2-transformation of the
protein ratio fold changes with respect to their measurements in the biological plasma refer-
ence sample. The sample preparation and all other manipulations relative to the MS measure-
ments are detailed further in previous work [34–36].
The SomaLogic protein measurements were characterized using the SOMAscan assay [17],
which relies on fluorescent labelling of poly-nucleotide aptamers targeting specific protein epi-
topes. Protein measurements were obtained in relative fluorescence unit and were then log2-
transformed. The SomaLogic panel targetted 1, 129 proteins; the KEGG and Reactome path-
ways covered by this panel are listed in S10 Table (enrichment using a 5% FDR threshold).
We discarded MS-based proteins if their measurements were missing for more than 5% of
the samples, leaving 210 proteins in the Ottawa cohort and 136 in the DiOGenes cohort; we
restricted all downstream analyses to the 133 proteins available for both cohorts. The SomaLo-
gic measurements had no missing values. Totals of 1, 100 and 1, 129 proteins were assayed in
the Ottawa and DiOGenes cohorts. All our analyses focused on the 1, 096 proteins quantified
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for both cohorts. The overlap between the MS and SomaLogic panels was of 72 proteins for
397 and 389 subjects in Ottawa and DiOGenes respectively.
We excluded samples with extreme expression values in more than 5% of the proteins, i.e.,
values beyond the outer fences of the empirical distribution (q1 − 3 × IQR, q3 + 3 × IQR, where
q1, q3 are the lower and upper quartiles, and IQR is the interquartile range). After this quality
control procedure, 577 and 428 Ottawa samples remained in the MS and SomaLogic datasets,
respectively, and 481 and 563 DiOGenes samples remained in the MS and SomaLogic datasets,
respectively.
Genotyping
Genotypes were generated using HumanCoreExome-12 v1.1 Illumina SNP arrays (Illumina,
Inc., San Diego, CA), according to their manufacturer’s instructions and were called with the
GenomeStudio Software provided by Illumina. Preprocessing steps, including imputation and
quality control, have been previously documented [37]. We discarded SNPs with call rate
<95%, violating Hardy–Weinberg equilibrium (FDR<20%), and we discarded subjects with
low call rate (<95%), abnormally high autosomal heterozygosity (FDR<1%), an XXY karyo-
type, or gender inconsistencies between genotype data and clinical records. For subjects with
identity-by-state IBS>95%, we kept only the one with the highest call rate. A table detailing
these quality control filters for the Ottawa and DiOGenes studies is given in S5 Appendix. The
subjects from both cohorts were of European ancestry and the two cohorts had similar genetic
structure. We used principal component analyses separately on each cohort to exclude subjects
that were extremely heterogeneous genetically. We performed genotype imputation using
SHAPEIT [38] and IMPUTE2 [39], based on the European reference panel from the 1, 000
Genome project (March 2012 release, phase 1 version 3). We then discarded SNPs with INFO
score <0.8, which left 4.9M imputed SNPs in both datasets. We applied a light LD pruning
with PLINK [40] using pairwise r2 threshold 0.95 and used a minor allele frequency threshold
of 5% after having restricted the genotype data to the subjects with available proteomic data.
The above steps were performed separately for the Ottawa and the DiOGenes cohorts, so in
order to define a common set of SNPs for discovery and replication, we restricted each dataset
to the SNPs available for both cohorts. After all genetic quality controls, and in both cohorts,
p = 275, 485 tag SNPs remained for the SomaLogic analysis and p = 275, 297 tag SNPs
remained for the MS analysis. As SNPs were imputed, the 0.95-r2 pruning led to a drastic cut
of “redundant” markers: without this pruning step, the number of SNPs was�4M. Such a
reduction is not surprising considering the nature of the underlying SNP arrays (essentially
based on tag SNPs) and indicates that little information was discarded. In the Ottawa cohort
n = 376 subjects had both genotype and MS proteomic data, and n = 394 subjects had both
genotype and SomaLogic proteomic data. In the DiOGenes cohort, these numbers were
n = 400 and 548.
Clinical data
Both cohorts had records on age, gender, anthropometric traits (weight and BMI), glycemic
variables (fasting glucose, fasting insulin, HOMA-IR), and total lipid levels obtained from
blood biochemistry (total cholesterol, triglycerides, HDL). We derived LDL values using the
Friedewald formula [41], and obtained gender-specific visceral adiposity index (VAI) values
using the formula of Amato et al. [42]. In each cohort and for each clinical variable, we
removed a few samples with extreme measurements, similarly as for the proteomic data quality
control.
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LOCUS: Fast Bayesian inference for joint QTL analysis
LOCUS is a variational inference approach for joint mapping analysis at the scale required by
current molecular QTL studies (Fig 1a) [14]. It implements a hierarchical model that involves
a collection of sparse regressions,
yt ¼ Xβt þ εt; εt � N nð0; t  1t InÞ; t ¼ 1; . . . ; q;
where y = (y1, . . ., yq) is an n × qmatrix of q centered outcomes (e.g., genomic, proteomic or
metabolomic levels), and X is an n × pmatrix of p centered candidate predictor SNPs, for each
of n samples. Each outcome, yt, is related linearly to all p candidate SNPs, and has a specific
residual precision, τt, to which we assign a Gamma prior, τt* Gamma(ηt, κt). The association
between each pair of SNP and outcome is modelled using a spike-and-slab prior, namely, for
s = 1, . . ., p and t = 1, . . ., q,
bst j gst; s
2; tt � gst N ð0; s2 t  1t Þ þ ð1   gstÞ d0; gst j os � BernoulliðosÞ;
where δ0 is the Dirac distribution. Hence, to each regression parameter βst corresponds a
binary latent parameter γst, which acts as a “predictor-outcome association indicator”: the
predictor Xs is associated with the outcome yt if and only if γst = 1. The parameter σ represents
the typical size of nonzero effects and is modulated by the residual scale, t
  1=2
t , of the outcome
concerned by the effect; it is inferred from the data using a Gamma prior specification,
σ−2 *Gamma(λ, ν). Finally, we let the probability parameter ωs have a Beta distribution,
os � Betaðas; bsÞ;
where as and bs are set so as to enforce sparsity as described in Ruffieux et al. [14]. Since it is
involved in the Bernoulli prior specification of all γs1, . . ., γsq, the parameter ωs controls the
proportion of outcomes associated with the predictor Xs, and hence directly represents the
propensity of predictors to be pleiotropic “hotspots”. Both ωs and σ2 allow the leveraging of
shared association patterns across all molecular variables, which enhances the estimation of
QTL effects; see the graphical representation of the model (Fig 1b). Thanks to this joint tai-
lored modelling, the inclusion of cis regions does not mask the weaker trans effects, but rather
modelling altogether cis and trans effects, possibly governed by shared mechanisms, contrib-
utes to boost the detection of trans signals. LOCUS estimates interpretable posterior probabili-
ties of association for all SNP-outcome pairs (Fig 1c), from which Bayesian false discovery
rates are easily calculated.
The Bayesian framework of LOCUS can be flexibly extended to account for population
structure, using a dedicated random effect parameter. Alternatively, adding genotypic princi-
pal components as fixed covariates in our model may suffice in some cases.
Inference on high-dimensional Bayesian models is both computationally and statistically
difficult. Previous joint QTL approaches [20, 43] are based on sampling procedures, such as
MCMC algorithms, and require prohibitive computational times on data with more than few
hundreds of SNPs or outcomes. LOCUS uses a fast deterministic variational inference algo-
rithm, which scales to the typical sizes of QTL problems. Previous work [14] compared
LOCUS with existing QTL methods, whether stochastic or deterministic, univariate or multi-
variate. Here, we augmented our algorithm with a simulated annealing procedure [44] to
enhance exploration of multimodal parameter spaces, as induced by strong linkage-disequilib-
rium (LD) structures. The pQTL study of two obesity cohorts described in the present paper
illustrates the strengths of our statistical framework in a concrete and thorough manner and
directly exploits these strengths for uncovering new signals of biological and clinical relevance.
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The applicability of a fully multivariate method to large molecular QTL data also hinges on
the effective computational implementation of its algorithmic procedure. The annealed varia-
tional updates of LOCUS are analytical and performed by batches of variables. The software is
written in R with C++ subroutines and is publicly available [45]. Our pQTL analyses com-
pleted in a few hours for 275K tag SNPs representing information from about 4M common
markers, yet larger SNP panels can be considered as our method scales linearly in terms of
memory and CPU usage. For instance, analyses of 2M SNPs and 1, 000 proteins run in less
than 40 hours (see profiling, S2 Appendix).
Simulation study design
We evaluated the performance of LOCUS expected on our data by conducting two simulation
studies. We compared its statistical power to detect pQTL associations with that of the linear
mixed model approach GEMMA [25, 26], which estimates the associations between each SNP
and each outcome in a univariate fashion. We used the R package echoseq [46] to generate
synthetic data that emulate real data; see S2 Appendix.
For the first simulation, we ran LOCUS and GEMMA on the SNPs of all n = 376 Ottawa
subjects, and on simulated expression outcomes with residual dependence replicating that of
the q = 133 MS proteomic levels. We used the SNPs from chromosome one (p = 20, 900), and
generated associations between 20 SNPs and 25 proteins chosen randomly, leaving the remain-
ing variables unassociated. Some proteins were under pleiotropic control; we drew the degree
of pleiotropy of the 20 SNPs from a positively-skewed Beta distribution, so only a few SNPs
were hotspots, i.e., were associated with many proteins. We generated associations under an
additive dose-effect scheme and drew the proportions of outcome variance explained by a
given SNP from a Beta(2, 5) distribution to give more weight to smaller effect sizes. We then
rescaled these proportions so that the variance of each protein attributable to genetic variation
was below 35%. These choices led to an inverse relationship between minor allele frequencies
and effect sizes, which is to be expected under natural selection. We generated 50 replicates,
re-drawing the protein expression levels and effect sizes for each. On top of comparing the rel-
ative performances of LOCUS and GEMMA on these data, we also illustrated the benefits of
modelling all the proteomic outcomes jointly by comparing the performance of LOCUS when
applied to increasingly larger batches of proteins. Namely, we split randomly the proteins into
batches of given sizes—ranging from 1, for a univariate modelling of the proteins, to all 133
MS proteins, for a fully multivariate treatment corresponding to a classical application of
LOCUS—and ran LOCUS separately on each batch and all SNPs from chromosome one. We
then aggregated posterior probabilities of inclusion to assess selection performance. This pro-
cedure was repeated for each of the 50 synthetic data replicates.
For the second simulation, we re-assessed the performance of LOCUS for a grid of data
generation scenarios. We considered a wide range of sparsity levels (numbers of proteins
under genetic control) and effect sizes (proportions of outcome variance explained by the
genetic variants). Given the large number of configurations (130), and in order to limit the
computational burden, we used the first p = 2, 000 SNPs, and ran LOCUS and GEMMA on 20
replicates for each configuration.
pQTL analyses
We performed pQTL analyses separately for each platform, i.e., one analysis for the MS prote-
omic dataset, and another for the SomaLogic proteomic dataset. Each analysis comprised two
stages: a discovery stage using the Ottawa cohort and a replication stage based on the DiOGe-
nes cohort.
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For discovery, we used LOCUS on both the MS and the SomaLogic datasets, with an
annealing schedule of 50 geometrically-spaced temperatures and initial temperature of 20;
pilot experiments indicated that estimation was not sensitive to these choices. We used a con-
vergence tolerance of 10−3 on the absolute changes in the objective function as the stopping
criterion. The algorithm can handle missing data in the outcome matrix, so no imputation was
necessary for the MS proteomic data.
We adjusted all analyses for age, gender, and BMI. No important stratification was observed
in the genotype data; the first ten principal components together explained little of the total
variance (<4%), so we did not include them as covariates. We derived FDR values from the
posterior probabilities of association obtained between each SNP and each protein, and
reported pQTL associations using an FDR threshold of 5%.
We performed a validation study of the pQTLs discovered using the DiOGenes cohort with
GEMMA [26, 47], with centered relatedness matrix (default) and p-values from (two-sided)
Wald tests. We then obtained adjusted p-values using Benjamini–Hochberg FDR, and vali-
dated our hits using again an FDR threshold of 5%.
Comparison with a standard two-stage univariate design
To assess the extent to which LOCUS two-stage pQTL analysis discovers more hits than the
univariate procedures routinely applied for e- or pQTL analyses, we re-performed the entire
study using GEMMA [25, 26]. We followed standard practices and ran the method separately
for the MS and SomaLogic analyses on the SNPs without LD pruning, i.e., on roughly 4 million
SNPs. We then corrected for multiple testing using a standard Bonferroni threshold of 0.05
(based on the numbers of tested SNPs and proteins) and also discussed the results obtained
with a more permissive Bonferroni threshold of 0.2.
To account for proxy hits arising from the SNP LD structure and provide grounds for com-
parison between GEMMA and LOCUS, we defined hits at the level of loci as follows: the hits
identified by GEMMA and/or LOCUS as associated with a same protein (quantified by the
same proteomic technology) were considered to be in a same locus if there was no more than
1Mb between two consecutive hits. The additional hits found by GEMMA at Bonferroni level
0.2 were assigned to the closest existing loci (mapping to the same protein), provided that the
distance was less than 1Mb; new loci were defined for the remaining hits.
pQTL annotation
We used the Ensembl database [48] (GRCh37, release 94) to retrieve the list of genes within
2Mb of each sentinel SNP (i.e., involved in the pQTL associations identified by LOCUS), and
also listed the SNPs in LD (r2 > 0.8), limiting the search to 500Kb upstream and downstream
of the sentinel SNP position. We called cis pQTLs, all sentinel SNPs located within ±1Mb of
the gene encoding for the controlled protein, and trans pQTLs, all other pQTLs.
We evaluated the overlap between our pQTL associations and previously reported pQTL
signals with the PhenoScanner database [49, 50], using the default p-value threshold p< 10−5
and an LD proxy search (r2 > 0.8, in populations with European ancestry). As queries using
the R package phenoscanner are limited to 500 returned tuples, we downloaded a local
copy of the database (retrieved on 26/03/2019). Moreover, since protein names in the database
do not follow the official UniProt protein names, we retrieved the annotation files from all
individual studies and remapped the protein names onto the official UniProt identifier,
thereby enabling the comparison with our pQTL hits using dbSNP rsIDs and UniProt IDs.
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Epigenomic annotation
We retrieved epigenomic annotations of 1, 000 Genomes Project (release 20110521) from
Pickrell [51]. The data covered 450 annotation features, each binary-coded according to the
presence or absence of overlap with the SNPs. The features corresponded to DNase-I hyper-
sensitivity sites, chromatin state, SNP consequences (coding, non-coding, 5’UTR, 3’UTR, etc),
synonymous and nonsynonymous status and histone modification marks. We obtained dis-
tances to the closest transcription start site from the UCSC genome browser [52]. Ninety-
seven of our 104 validated sentinel SNPs had annotation data; to evaluate their functional
enrichment, we resampled SNP sets of size 97 from our initial SNP panel, and, for each set, we
computed the cumulated number of annotations. We did the same for the distances to tran-
scription start sites. We repeated this 105 times to derive empirical p-values.
Overlap with known eQTLs and with GWAS risk loci
We evaluated the overlap of our pQTLs with the eQTL variants reported by the GTEx Consor-
tium [53, 54] (release 7) at q-value<0.05. We considered all 49 tissues listed by GTEx but
eQTL SNPs for several tissues were counted only once. We made both general queries and
queries asking whether a pQTL uncovered by LOCUS was an eQTL for the gene coding for
the controlled protein.
We retrieved known associations between the validated sentinel pQTLs and diseases or
clinical traits, based on the GWAS catalog [55, 56] (v1.0 release e92), and also using an LD
proxy search (r2 > 0.8).
We evaluated enrichment for eQTL and risk loci using one-sided Fisher exact tests based
on the 104 validated sentinel pQTLs.
Associations with clinical variables
We tested associations between the proteins under genetic control and clinical parameters sep-
arately in each cohort. For the DiOGenes data, we used linear mixed-effect models, adjusting
for age, gender as fixed effects, and center as a random effect. For the Ottawa data, we used lin-
ear models, adjusting for age and gender. Except when testing associations with anthropomor-
phic traits, all analyses were also adjusted for BMI. For the clinical variables available in the
two cohorts (total cholesterol, HDL, LDL, fasting glucose, fasting insulin, HOMA-IR, triglycer-
ides and VAI), we performed meta-analyses using the R package metafor [57]. We used ran-
dom-effects models to account for inter-study variability, which may in part result from
geographical differences, and employed two-sided Wald tests for fixed effects, and Cochran Q-
tests for measuring residual heterogeneity; we did not interpret the results if between-study
heterogeneity estimates were high (I2 > 80%), and evaluated the directional consistency of the
effects between Ottawa and DiOGenes. We adjusted for multiplicity using Benjamini–Hoch-
berg correction across all tests, i.e., involving the 88 tested proteins and the two proteomic
technologies, and reported associations using a 5% FDR threshold.
We assessed whether the proteins under genetic control were enriched in associations with
the clinical variables. We randomly selected 105 sets of 88 proteins from the panel used for the
pQTL analyses and derived an empirical p-value by counting, for each set, the number of pro-
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Formal analysis: Hélène Ruffieux, Armand Valsesia.
Investigation: Hélène Ruffieux, Armand Valsesia.
Methodology: Hélène Ruffieux, Anthony C. Davison, Armand Valsesia.
Project administration: Jörg Hager, Armand Valsesia.
Resources: Radu Popescu, Mary-Ellen Harper, Robert Dent, Wim H. M. Saris, Arne Astrup,
Jörg Hager.
PLOS COMPUTATIONAL BIOLOGY A fully joint Bayesian QTL mapping of human protein abundance in plasma
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007882 June 3, 2020 21 / 24
Software: Hélène Ruffieux.
Supervision: Anthony C. Davison, Armand Valsesia.
Validation: Hélène Ruffieux, Armand Valsesia.
Visualization: Hélène Ruffieux, Armand Valsesia.
Writing – original draft: Hélène Ruffieux, Anthony C. Davison, Armand Valsesia.
Writing – review & editing: Hélène Ruffieux, Anthony C. Davison, Armand Valsesia.
References
1. Gallagher MD, Chen-Plotkin AS. The post-GWAS era: from association to function. The American Jour-
nal of Human Genetics. 2018; 102:717–730. https://doi.org/10.1016/j.ajhg.2018.04.002
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